The Certara, Inc. (NASDAQ: CERT) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Certara is a biosimulation and model‑informed drug development company whose common stock is registered on The Nasdaq Stock Market LLC under the symbol CERT, as disclosed in its Form 8‑K filings.
Investors can review current reports on Form 8‑K, which Certara uses to announce material events. Recent 8‑K filings include press releases for quarterly financial results, where the company reports revenue from biosimulation software and services, bookings, and updates to its full‑year financial outlook. Other 8‑K filings document corporate developments such as amendments to the company’s credit agreement and leadership changes, including the appointment of a new chief executive officer.
In addition to 8‑K reports, users can expect to find annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available), which typically provide more detailed discussions of Certara’s business, risk factors, and financial statements. Filings related to financing arrangements, such as amendments to term loan facilities, are also included and can offer insight into the company’s capital structure and borrowing costs.
Related filing summaries include AI‑powered summaries that explain key sections of lengthy filings, helping readers quickly identify important information without reading every page. Real‑time updates from EDGAR ensure that new Certara filings appear promptly, while dedicated sections surface insider transaction reports on Form 4 and other ownership‑related disclosures when they are filed.
By using this page, investors and researchers can follow Certara’s regulatory reporting history, track material events, and better understand how the company describes its biosimulation software, services, and financial performance in official SEC documents.
Certara, Inc. reported flat revenue but a swing to loss in its latest quarter. For the three months ended March 31, 2026, revenue was $106.9 million, up slightly from $106.0 million a year earlier, while net results moved from $4.7 million profit to a $8.8 million loss, or basic and diluted loss of $0.06 per share.
Operating income declined to a $4.3 million loss as general and administrative and research and development expenses increased. Cash and cash equivalents fell from $189.4 million at year-end to $149.5 million, driven largely by $40 million of share repurchases and ongoing investment in software development.
The company ended the quarter with $294.8 million of term-loan debt and total stockholders’ equity of $1.02 billion. Bookings were $115.3 million with a software net retention rate of 106.1%, indicating expansion within the existing customer base. After quarter end, Certara closed the sale of its global medical writing and related regulatory services business, expecting to recognize a loss estimated between $28.9 million and $53.7 million on that divestiture.
Certara, Inc. reported first quarter 2026 revenue of $106.9 million, up 1% year over year, with 7% growth in software offset by a 4% decline in services. The company swung to a net loss of $8.8 million versus $4.7 million of net income a year earlier, mainly due to higher operating expenses.
Certara closed the sale of its global medical and regulatory writing business to Veristat for $85 million in cash, plus $15 million in escrow and up to $35 million in potential earn-out. Full-year 2026 guidance now calls for $395–$405 million of revenue and adjusted EBITDA margin of about 30%–32%.
Certara, Inc. has entered into a definitive agreement to sell its global Regulatory and Medical Writing business to Veristat. The deal values the business at up to $135 million, including $100 million in cash at closing, subject to customary working capital and other adjustments, plus up to $35 million of contingent earn-out based on future performance. Up to $15 million of the closing payment may be placed in escrow until certain items are satisfied.
The business generated $50 million of revenue and $17 million of adjusted EBITDA in 2025 and includes approximately 220 employees. Certara describes the divestiture as sharpening its focus on Model-Informed Drug Development and Clinical Intelligence, and plans to update its 2026 guidance after the transaction closes, which is expected in the second quarter of 2026, subject to customary conditions.
Wasatch Advisors files an amendment to its Schedule 13G/A reporting beneficial ownership of 5,272,166 shares of Certara Inc. This position represents 3.3% of the outstanding common stock and shows sole voting power over 3,598,349 shares and sole dispositive power over all 5,272,166 shares. The filing is signed by the reporting CEO on 04/06/2026.
Certara Inc Schedule 13G/A amendment shows Wasatch Advisors reports 5,272,166 shares of Common Stock, representing 3.3% of the class. The filing lists 3,598,349 shares with sole voting power and 5,272,166 with sole dispositive power. The filing is signed on 04/06/2026.
Certara, Inc. president and chief commercial officer Leif E. Pedersen reported vesting and settlement of stock awards on April 1, 2026. He exercised restricted stock units and performance stock units to receive 33,167 shares of common stock at an exercise price of $0.00 per share.
He also received a separate award of 14,510 shares of common stock, while 11,611 shares were withheld at $5.70 per share to satisfy tax obligations tied to the RSU and PSU vesting. Following these compensation-related transactions, he directly holds 110,045 shares of Certara common stock.
Certara, Inc. executive Adrian McKemey, President, Drug Development Solutions, exercised 10,849 restricted stock units into common shares on April 1, 2026 at a stated price of $0.00 per share. These RSUs were granted on May 20, 2025 under Certara’s 2020 Incentive Plan.
In connection with vesting, 2,642 common shares valued at $5.70 per share were withheld to satisfy tax obligations, a non-market, tax-withholding disposition exempt under Rule 16b-3. After these transactions, McKemey directly holds 8,207 common shares and 21,698 unvested RSUs scheduled to vest in equal parts on April 1, 2027 and April 1, 2028.
Certara, Inc. SVP and General Counsel Daniel Corcoran exercised restricted stock units into common shares as part of his equity compensation. On April 1, 2026, one-third of a prior RSU grant vested and settled, delivering 10,849 shares of common stock. Of these, 5,751 shares were withheld at $5.70 per share to cover tax obligations, a non-market, tax-withholding disposition. Following these transactions, Corcoran directly held 21,319 shares of Certara common stock. The remaining RSUs from this grant are scheduled to vest and settle in equal parts on April 1, 2027 and April 1, 2028.
Certara, Inc. Chief Financial Officer John E. Gallagher reported a series of equity compensation transactions involving restricted stock units (RSUs), performance stock units (PSUs), and related common stock on April 1, 2026.
He exercised or converted derivative awards into a total of 50,605 shares of common stock and received an additional grant or award of 23,346 common shares. Following these transactions, he directly owned 95,371 shares of Certara common stock.
The filing also shows 25,108 shares of common stock were disposed of to satisfy tax withholding obligations at prices including $5.70 per share, rather than through open-market sales. Footnotes explain that the PSUs and RSUs were granted under Certara’s 2020 Incentive Plan and vested based on multi-year service and performance schedules.
Certara, Inc. executive Robert Aspbury, President, Predictive Tech, reported multiple equity compensation events on April 1, 2026. Previously granted performance stock units and restricted stock units vested and were settled into a total of 33,167 shares of common stock, consistent with the filing’s exercise summary.
To cover related tax obligations, the company withheld 22,411 shares at $5.70 per share under code F, a non‑market, tax-withholding disposition exempt under Rule 16b-3. Aspbury also received a 14,510-share common stock award as compensation and, following these transactions, directly owned 332,442 shares of Certara common stock.